QTTB vs LLY

Q32 Bio Inc.

(QTTB) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Q32 Bio Inc.

(QTTB) is the cheapest at 5. 2x versus Eli Lilly and Company at 50. 6x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +429.

1%, compared to -90. 2% for Q32 Bio Inc. (QTTB). Over 10 years, the gap is even starker: LLY returned +1522% versus QTTB's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

53β versus Q32 Bio Inc. 's 0. 62β — meaning QTTB is approximately 15% more volatile than LLY relative to the S&P 500. On balance sheet safety, Q32 Bio Inc. (QTTB) carries a lower debt/equity ratio of 37% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Q32 Bio Inc.

grew EPS 136. 8% year-over-year, compared to 96. 0% for Eli Lilly and Company. Over a 3-year CAGR, QTTB leads at 100. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Q32 Bio Inc.

(QTTB) is the more profitable company, earning 55. 5% net margin versus 31. 7% for Eli Lilly and Company — meaning it keeps 55. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 31. 5% for QTTB. At the gross margin level — before operating expenses — QTTB leads at 99. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LLY: 9.

1% to $1266. 17.

In this comparison, LLY (0.

5% yield) pays a dividend. QTTB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1522% 10Y return). Both have compounded well over 10 years (LLY: +1522%, QTTB: -96. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: QTTB is a small-cap deep-value stock; LLY is a mega-cap high-growth stock. LLY pays a dividend while QTTB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.